Oncopharmpod
HER2 Mutated NSCLC
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:14:59
- Mas informaciones
Informações:
Sinopsis
In light of trastuzumab deruxtecan's approval for HER-mutated NSCLC, it's worthwhile to look back at the history of HER-targeted therapy in NSCLC and why/how targeted HER-mutated disease will affect practice.
